EXIT: Prospective Study of the Response to Exercise (EXIT)
Exercise and Irisin Trial (EXIT): Prospective Cohort Study of the Determinants of the Metabolic Response to Exercise in Obese Adolescents
Background :
Regular exercise is a cornerstone in the prevention and the management of comorbidities. Unfortunately, the metabolic benefit of exercise training is not universal and varies among individuals. A main factor likely to explain the exercise training variability is the lack of empirical evidence on the determinants of exercise training. A series of muscle-derived cytokines have recently been discovered that (1) are released during exercise and (2) exert positive effects on peripheral tissues. Irisin is one of these novel "myokines" and might contributes to the metabolic adaptations to exercise training.
Methods:
The investigators will perform a pilot cohort study in which obese adolescents will perform resistance exercise training for 6 weeks. The main exposure variable will be the acute release of irisin during resistance exercise. The main outcome measures will be the change in hepatic triglyceride content and glucose area under the curve during a 75g, 2-hour oral glucose tolerance test.
Study Hypothesis:
The primary overall hypothesis is that the change in plasma Irisin with a single bout of exercise will be associated with the metabolic adaptations to 6 weeks of resistance training, specifically, the reductions in hepatic triglyceride content and post-prandial glucose excursions, in obese adolescents.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Winnipeg, Canada
- The Manitoba Institute of Child Health
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Adolescents (12-18 years)
- Body mass index considered obese according to the International Obesity Task Force
Exclusion Criteria:
- Adolescents with medication-induced or type 1 diabetes
- are currently being treated with corticosteroids or atypical antipsychotics, as these agents significantly influence carbohydrate metabolism
- have an orthopaedic injury or chronic illness that would prevent them from performing the intervention
- have experienced >10% weight loss or enrolled in weight loss program within six months of enrolment
- a history of alcoholism or drug abuse
- require use of medication(s) known to affect insulin sensitivity or secretion within the last 30 days
- medication(s) known to cause weight gain
- anabolic steroids
- weight loss medication(s)
- pregnant or planning to be pregnant
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Overweight Adolescents Performing Resistance Training
Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period.
Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training.
This will be the primary exposure variable.
After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks.
During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
|
We will determine the amount of Irisin secreted after a single bout of resistance exercise.
Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise.
The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hepatic Triglyceride Content
Lasso di tempo: 6 weeks
|
Hepatic triglyceride content will be measured by using 1H magnetic resonance spectroscopy.
After image acquisition, a single voxel volume of interest will be placed in the upper right lobe of the liver in an area devoid of adipose tissue to acquire 1H spectra.
A total of 64 spectra will be collected and averaged to determine the intracellular triglyceride content.
|
6 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Post-prandial glucose
Lasso di tempo: 6 weeks
|
Glucose area under the curve (AUC) will be determined by summing the area under serum glucose measures between each 15- or 30-min segment using the trapezium rule during a frequently sampled 75-g oral glucose challenge .
|
6 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jon M McGavock, PhD, University of Manitoba
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- B2014:064
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Grasso di fegato
-
Juva Skin & Laser CenterAllerganCompletatoReggiseno Strap Fat (BSF) | Reggiseno Strap Fat (BSF)Stati Uniti
-
Medical College of WisconsinRitiratoModello alto per il punteggio MELD (end-stage Liver Disease).Stati Uniti